"Hämato-Onkologischer Studienkreis MVZ am Klinikum Aschaffenburg / Onkologie"
Welcome,         Profile    Billing    Logout  
 10 Trials 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Welslau, Manfred
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label

Recruiting
4
108
Europe
Ontruzant, SB3, Chemotherapy, Pertuzumab
Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd.
Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer
01/22
01/23
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Checkmark [VIRTUAL] Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial
Recruiting
3
593
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
03/24
03/24
NCT02131753: Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Recruiting
2/3
210
Europe
Cladribine s.c. injection, HCL treatment, Litak(R), 2-CdA
University of Giessen
Hairy Cell Leukemia
12/22
12/27
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

Recruiting
2
196
Europe
Aflibercept + mLV5FU2, mFOLFOX7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi
Colorectal Cancer
03/22
09/22
AIO-STO-0417, NCT03647969 / 2017-002080-18: Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Checkmark [VIRTUAL] Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase .…
Checkmark Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Grou…
Checkmark Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group…
Recruiting
2
257
Europe
Nivolumab, Ipilimumab, mFOLFOX, FLOT
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Adenocarcinoma of the Stomach, GastroEsophageal Cancer
07/22
12/22
NCT04581824: Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Checkmark Initiate phase 2 trial for metastatic NSCLC
Recruiting
2
240
Europe, US, RoW
Dostarlimab, Pembrolizumab, Chemotherapy
GlaxoSmithKline
Lung Cancer, Non-Small Cell
09/22
11/25
NCT03731832: Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Recruiting
2
82
Europe
MLN9708, Ixazomib 4.0 mg, Pomalidomide 4 MG Oral Capsule, Dexamethasone, Cyclophosphamide
GWT-TUD GmbH
Refractory Multiple Myeloma
12/23
12/24
IMPACT, NCT04030728: Implementing Patients´ Competence in Oral Breast Cancer Therapy

Not yet recruiting
N/A
212
NA
Onco Medical Consult GmbH, Eli Lilly and Company, Institut fuer Frauengesundheit
Metastatic Breast Cancer, Advanced Breast Cancer
09/21
12/21
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project

Checkmark [VIRTUAL] GENOMIC LANDSCAPE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 70 YEARS
Checkmark [VIRTUAL] Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls
Checkmark [VIRTUAL] IVOSIDENIB IMPROVES OVERALL SURVIVAL RELATIVE TO STANDARD THERAPIES IN RELAPSED OR REFRACTORY MUTANT IDH1 AML: RESULTS FROM MATCHED COMPARISONS TO HISTORICAL CONTROLS
Checkmark Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification
Checkmark MOLECULAR PROFILES IN AML PATIENTS OLDER THAN 70 YEARS OF AGE
More
Recruiting
N/A
Europe
University of Ulm
Acute Myeloid Leukemia (AML), Higher Risk Myelodysplastic Syndromes (MDS With Excess Blasts 2)
 
 
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Recruiting
N/A
500
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25

Download Options